Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

0 days.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Six-month results from the Phase 2 efficacy study demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in the study.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to www.medivation.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Liti
'"/>




Page: 1 2 3

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:1/6/2009)...E, Md., Jan. 6 Sequella... focused on diseases of epidemic potential, announ...the treatment of tuberculosis (TB), was the first ...inical program contract to Dynport Vaccine Company...arded by the National Institute of Allergy and Inf...
(Date:1/5/2009)...ESDA, Md., Jan. 5 Microm...ompany developing novel, proprietary,antibodies f...mmune diseases,provides an outlook on key events...t intends to provide an update on its research and..., -- April 12 to 16, 2009: Update on several ...
(Date:12/27/2008)...D,S, Bermuda, Dec. 23 Wa...today that one of its subsidiaries and Mayne Pharm...of Hospira, Inc., have filed lawsuits against each..., Mylan Pharmaceuticals Inc. ("Mylan") and Impax L... for the District of New Jersey for infringement o...
(Date:12/17/2008)...est, Most Complex of Its Kind; 80 Percent of Traum..., Dec. 17 A multi-disciplinary tea...ntly performed the first near-total face transpla...procedure performed within the past two weeks, sur...o suffered severe facial trauma -- essentially rep...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 1ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 2China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 1China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 2AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2
...ce suggests that if you,could choose your parents,...ase. Researchers from the long-standing,Framingham...t,Lung, and Blood Institute (NHLBI) of the Nation...parents live longer were more,likely to avoid deve...other risk factors for cardiovascular disease in m...
...3, 2007 -,Cytos Biotechnology AG (SWX:CYTN) report...ith CYT003-QbG10, an immunotherapeutic,product can... study,included 40 patients suffering from mild to...lergy (hay fever). The trial,investigated in a dou...oratory efficacy of two different formulations of ...
Other Medicine Technology:Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:1/8/2009)...y could shape new treatments for secondary pneumon...swire/ -- Scientists at St. Jude Children,s Resear...atment for bacterial pneumonia following influenza...azithromycin, which kill bacteria by inhibiting th...tandard first-line treatment with the "beta-lactam...
(Date:1/8/2009)... hurtful comments, study suggests , , T...erestimate how strongly they would react to racist...e percent of study participants at York University...ment with a white person rather than a black one, ...bout the black person when he left the room. ,...
(Date:1/8/2009)...ldren,s Research Hospital have demonstrated a more...wing influenza. They found that the antibiotics cl... inhibiting their protein synthesis, are more effe...e "beta-lactam" antibiotic ampicillin, which cause...g is important because pneumonia, rather than the ...
(Date:1/8/2009)...PRNewswire-FirstCall/ -- Hanger Orthopedic Group, ...roughout the fourth quarter of 2008 it acquired Ma...ountain Orthotic-Prosthetics Center, Riessen,s Ort... Orthotics & Prosthetics, and Orthopedic Rehab...tient care centers to existing markets in Maine, L...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...apeutic regimens are effective in suppressing HIV ... treatment may be complicated by development of dr...e // continued concerns over the safety of interru...clinical practice interrupt therapy for reasons re...
... reported at a seniors' home in Toronto and expert... caused the death of four residents at the home. I...here was // no cause to fear an outbreak and stres...e, "This isn't a pandemic by any means, but there ...
...arch in the areas of fetal imaging focus on modali...t women, their unborn babies and newborns with MR ...les diagnosis and treatment of many // disorders t...elayed intervention.. Fetal MRI is usually perform...
...rized by insulin resistance and/or abnormal insuli...inues to expand unabated throughout the world. The...to decreased physical activity, decreased function..., preexisting glucose and insulin abnormalities, a...
Other Medicine News:Health News:Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease 2
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: